The Latest Progress in the Application of Telitacicept in Autoimmune Diseases
Baocheng Liu,Yaqi Zhao,Dongxia Liu,Xinya Li,Zhenzhen Ma,Qingrui Yang
DOI: https://doi.org/10.2147/dddt.s493923
IF: 4.3188
2024-12-08
Drug Design Development and Therapy
Abstract:Baocheng Liu, 1, &ast Yaqi Zhao, 2, &ast Dongxia Liu, 1 Xinya Li, 1 Zhenzhen Ma, 1, 2 Qingrui Yang 1, 2 1 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, People's Republic of China; 2 Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhenzhen Ma; Qingrui Yang, Email ; Introduction: Humoral immunity plays a key role in the pathogenesis of autoimmune diseases, and B-lymphocyte activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are essential for the maintenance of B-lymphocyte reservoirs and humoral immunity. In March 2021, telitacicept, the world's first dual target three-channel biologic, was approved in China for the treatment of SLE and is currently in clinical trials exploring multiple indications for other autoimmune diseases. Areas Covered: This article summarizes the mechanism of action, pharmacokinetics, and clinical efficacy of telitacicept for the treatment of multiple autoimmune diseases. Expert Opinion: So far, the efficacy and safety of telitacicept in autoimmune diseases have been fully demonstrated in clinical practice. There are still many unresolved issues regarding the timing of initiation and discontinuation, still needs to be evaluated in future studies. Keywords: biological therapy, autoimmune disease, B lymphocytes, telitacicept, immunology Autoimmune diseases are thought to be disorders in which the body's autoimmune system does not recognize normal cells (intracellular components) or tissues, further stimulating the body's immune response to produce autoantibodies, leading to local inflammatory reactions that eventually induce lesions or damage to tissues and organs, 1 which are associated with high morbidity and mortality, 2,3 and the treatment still faces real challenges that need to be resolved. With in-depth exploration of the pathogenesis of autoimmune diseases and the rapid development of biomedical research, telitacicept has been increasingly used in the treatment of autoimmune diseases. In this review, we will analyze the dosage, pharmacological mechanism, metabolic characteristics, and clinical application of telitacicept to help clinical physicians understand the latest research progress of telitacicept in autoimmune diseases, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), IgA nephropathy, myasthenia gravis (MG) and rheumatoid arthritis (RA). Table 1 Summary of Clinical Trials for Different Diseases BAFF, also known as B lymphocyte stimulator (BLyS), and its proliferation-inducing ligand, APRIL, have been shown to be extremely potent B-lymphocyte growth factors. 4 Studies found that BAFF binds to its receptor and plays an important role in the regulation of B lymphocyte maturation, proliferation, and activation. 5,6 The specific mechanism is mainly related to the three regulatory targets downstream of BAFF: BAFF has higher affinity for BAFF receptor (BAFFR) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) than B lymphocyte maturation antigen (B-cell maturation antigen, BCMA). BAFFR is widely distributed in all B lymphocytes except memory cells, and has been shown to maintain B lymphocyte apoptosis inhibitory factor levels through non-classical and classical NF-κB pathways activated by IκB kinase 1 (IKK1) and IκB kinase 2 (IKK2); BAFFR is also essential for the survival and maturation of transitional B lymphocytes and immature B lymphocytes. 7,8 TACIs are predominantly distributed across all B lymphocytes except naïve B lymphocytes, TACI maintains plasma cell survival by affecting the NF-κB pathway; upregulation of TACI levels mediates T-cell-independent B-lymphocyte responses to antigens (for instance, marginal zone B-lymphocytes and follicular B-lymphocytes). BCMA, a cell surface receptor of the tumor necrosis superfamily required for plasma cell survival, is responsible for plasma cell differentiation and survival. The three receptors, BAFFR, TACI and BCMA, play different roles at different times in the development of B lymphocytes to ensure its differentiation and maturation (Figure 1). The fusion protein of the human IgG1 Fc segment of telitacicept binds to the specific soluble extracellular portion of TACI (Figure 2), and the TACI receptor has a strong affinity for BLyS and APRIL. Telitacicept inhibits the further development and maturation of immature B lymphocyte -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal